The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

Ciprofol was superior to propofol in inducing anesthesia for colonoscopy as it resulted in lower injection pain and blood pressure reduction.

Hypochondria can, in extreme cases, leave people unable to hold down a job or make it impossible for them to leave the house, ...

High blood pressure, also called hypertension, is often referred to as a “silent killer” because it doesn’t always show ...

When Tara Garcia was born, her skin was tinted blue. This meant a lack of oxygen in her body. Doctors told her parents the ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

StudyFinds' Dr. Faith Coleman reveals her tips for maintaining good sexual function, even as men reach their senior years.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...